Dinona Inc.

Aprogen Inc.

Aprogen Kic Inc.

Kumho Ht, Inc.

Kwon Pyo Hong

Sangsoon Yoon

Gil Yong Ji

George Kopsidas

David S Wilson, Jr

Yoo Ri Moon

Vincent Batori

Irene Koukoulas

Briony Cristiano

Soseul Kim

Young Hoon Lim

Mi Hyang Shin

Eui Sup Lee

The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.

Antibody binding specifically to CD40 and use thereof

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Anti-CD43 antibody and use thereof for cancer treatment

The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.

Antibody binding specifically to CD66c and use thereof

A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.

Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent

Growing community of inventors

Cheongju-si, South Korea

Kwon Pyo Hong